Dialysis Co. Pays $7.3M To Settle FCA Overbilling Claims

Law360, Washington (May 21, 2013, 6:21 PM EDT) -- Dialysis company U.S. Renal Care agreed to pay $7.3 million to settle whistleblower allegations that a Maryland subsidiary violated the False Claims Act by excessively charging Medicare for the anemia drug Epogen, the U.S Department of Justice announced Tuesday.

The DOJ alleged that Dialysis Corp. of America, a Maryland-based acquisition of U.S. Renal Care, charged Medicare for 10 to 11 percent more of the anemia drug than it used during dialysis treatments from 2004-11. The drug is often administered during dialysis treatment, as anemia is a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.